Patents by Inventor John S. Sack
John S. Sack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230051701Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.Type: ApplicationFiled: May 5, 2022Publication date: February 16, 2023Inventors: Nils Lonberg, Alan J. Korman, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Ming Lei, Emanuela Sega, Angela Goodenough, Maria N. Jure-Kunkel, Guodong Chen, John S. Sack, Richard Huang, Martin J. Corbett, Joseph E. Myers, JR., Liang Schweizer, Sandra V. Hatcher, Haichun Huang, Pingping Zhang
-
Patent number: 11352440Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.Type: GrantFiled: August 30, 2018Date of Patent: June 7, 2022Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Nils Lonberg, Alan J. Korman, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Ming Lei, Emanuela Sega, Angela Goodenough, Maria N. Jure-Kunkel, Guodong Chen, John S. Sack, Richard Y. Huang, Martin J. Corbett, Joseph E. Myers, Jr., Liang Schweizer, Sandra V. Hatcher, Haichun Huang, Pingping Zhang
-
Publication number: 20190284293Abstract: Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-CD73 antibody in combination with an immuno-oncology agent, such as an anti-PD-1 antibody.Type: ApplicationFiled: March 3, 2017Publication date: September 19, 2019Inventors: Nils LONBERG, Alan J. KORMAN, Bryan C. BARNHART, Aaron P. YAMNIUK, Mohan SRINIVASAN, Karla A. HENNING, Ming LEI, Emanuela SEGA, Angela GOODENOUGH, Maria JURE-KUNKEL, Guodong CHEN, John S. SACK, Richard Y. HUANG, Martin J. CORBETT, Joseph E. MYERS, Jr., Liang SCHWEIZER, Sandra V. HATCHER, Rachel A. ALTURA, Haichun HUANG, Pingping ZHANG, Edward J. HILT, Michael Nathan HEDRICK
-
Publication number: 20190062456Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.Type: ApplicationFiled: August 30, 2018Publication date: February 28, 2019Inventors: Nils Lonberg, Alan J. Korman, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Ming Lei, Emanuela Sega, Angela Goodenough, Maria Jure-Kunkel, Guodong Chen, John S. Sack, Richard Y. Huang, Martin J. Corbett, Joseph E. Myers, JR., Liang Schweizer, Sandra V. Hatcher, Haichun Huang, Pingping Zhang
-
Publication number: 20190055320Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.Type: ApplicationFiled: August 27, 2018Publication date: February 21, 2019Inventors: Nils LONBERG, Alan J. KORMAN, Bryan C. BARNHART, Aaron P. YAMNIUK, Mohan SRINIVASAN, Karla A. HENNING, Ming LEI, Emanuela SEGA, Angela GOODENOUGH, Maria JURE-KUNKEL, Guodong CHEN, John S. SACK, Richard Y. HUANG, Martin J. CORBETT, Joseph E. MYERS, JR., Liang SCHWEIZER, Sandra V. HATCHER, Haichun HUANG, Pingping ZHANG
-
Patent number: 10167343Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.Type: GrantFiled: February 14, 2017Date of Patent: January 1, 2019Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Nils Lonberg, Alan J. Korman, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Ming Lei, Emanuela Sega, Angela Goodenough, Maria N. Jure-Kunkel, Guodong Chen, John S. Sack, Richard Y. Huang, Martin J. Corbett, Joseph E. Myers, Jr., Liang Schweizer, Sandra V. Hatcher, Haichun Huang, Pingping Zhang
-
Patent number: 10100129Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.Type: GrantFiled: November 19, 2015Date of Patent: October 16, 2018Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Nils Lonberg, Alan J. Korman, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Ming Lei, Emanuela Sega, Angela Goodenough, Maria Jure-Kunkel, Guodong Chen, John S. Sack, Richard Y. Huang, Martin J. Corbett, Joseph E. Myers, Jr., Liang Schweizer, Sandra V. Hatcher, Haichun Huang, Pingping Zhang
-
Publication number: 20180127513Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.Type: ApplicationFiled: November 19, 2015Publication date: May 10, 2018Inventors: Nils LONBERG, Alan J. KORMAN, Bryan C. BARNHART, Aaron P. YAMNIUK, Mohan SRINIVASAN, Karla A. HENNING, Ming LEI, Emanuela SEGA, Angela GOODENOUGH, Maria JURE-KUNKEL, Guodong CHEN, John S. SACK, Richard Y. HUANG, Martin J. CORBETT, Joseph E. MYERS, JR., Liang SCHWEIZER, Sandra V. HATCHER, Haichun HUANG, Pingping ZHANG
-
Publication number: 20170253665Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.Type: ApplicationFiled: February 14, 2017Publication date: September 7, 2017Inventors: Nils LONBERG, Alan J. KORMAN, Bryan C. BARNHART, Aaron P. YAMNIUK, Mohan SRINIVASAN, Karla A. HENNING, Ming LEI, Emanuela SEGA, Angela GOODENOUGH, Maria N. JURE-KUNKEL, Guodong CHEN, John S. SACK, Richard HUANG, Martin J. CORBETT, Joseph E. MYERS, JR., Liang SCHWEIZER, Sandra V. HATCHER, Haichun HUANG, Pingping ZHANG
-
Patent number: 9605080Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.Type: GrantFiled: January 13, 2016Date of Patent: March 28, 2017Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Nils Lonberg, Alan J. Korman, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Ming Lei, Emanuela Sega, Angela Goodenough, Maria N. Jure-Kunkel, Guodong Chen, John S. Sack, Richard Huang, Martin J. Corbett, Joseph E. Myers, Jr., Liang Schweizer, Sandra V. Hatcher, Haichun Huang, Pingping Zhang
-
Publication number: 20160145350Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.Type: ApplicationFiled: January 13, 2016Publication date: May 26, 2016Inventors: Nils Lonberg, Alan J. Korman, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Ming Lei, Emanuela Sega, Angela Goodenough, Maria N. Jure-Kunkel, Guodong Chen, John S. Sack, Richard Huang, Martin J. Corbett, Joseph E. Myers, JR., Liang Schweizer, Sandra V. Hatcher
-
Patent number: 7225083Abstract: The first crystal structure of the androgen receptor ligand binding domain has been determined to 2.0 angstrom resolution. Disclosed are the coordinates for the crystal structure, and methods for determining agonists, partial agonists, antagonists, partial antagonists and selective androgen receptors modulators (SARMs) of the androgen receptor.Type: GrantFiled: June 28, 2004Date of Patent: May 29, 2007Assignee: Bristol-Myers Squibb CompanyInventors: Roberto Weinmann, Howard M. Einspahr, Stanley R. Krystek, John S. Sack, Mark E. Salvati, John S. Tokarski, Ricardo M. Attar, Chihuei Wang
-
Patent number: 6960474Abstract: Selective androgen receptor modulators (SARMs) having antagonist activity in hormone-dependent tumors while exhibiting no activity or agonist activity against other nontumor tissues containing the androgen receptor as well as methods for identifying, designing and using SARMs are provided.Type: GrantFiled: June 20, 2001Date of Patent: November 1, 2005Assignee: Bristol-Myers Squibb CompanyInventors: Mark E. Salvati, Marco M. Gottardis, Ricardo M. Attar, Stanley R. Krystek, Jr., John S. Sack
-
Publication number: 20040243316Abstract: The first crystal structure of the androgen receptor ligand binding domain has been determined to 2.0 angstrom resolution. Disclosed are the coordinates for the crystal structure, and methods for determining agonists, partial agonists, antagonists, partial antagonists and selective androgen receptors modulators (SARMs) of the androgen receptor.Type: ApplicationFiled: June 28, 2004Publication date: December 2, 2004Inventors: Roberto Weinmann, Howard M. Einspahr, Stanley R. Krystek, John S. Sack, Mark E. Salvati, John S. Tokarski, Ricardo M. Attar, Chihuei Wang
-
Patent number: 6795776Abstract: The first crystal structure of the androgen receptor ligand binding domain has been determined to 2.0 angstrom resolution. Disclosed are the coordinates for the crystal structure, and methods for determining agonists, partial agonists, antagonists, partial antagonists and selective androgen receptors modulators (SARMs) of the androgen receptor.Type: GrantFiled: October 13, 2000Date of Patent: September 21, 2004Assignee: Bristol-Myers Squibb CompanyInventors: Roberto Weinmann, Howard M. Einspahr, Stanley R. Krystek, John S. Sack, Mark E. Salvati, John S. Tokarski, Ricardo M. Attar, Chihuei Wang
-
Publication number: 20020173445Abstract: Selective androgen receptor modulators (SARMs) having antagonist activity in hormone-dependent tumors while exhibiting no activity or agonist activity against other nontumor tissues containing the androgen receptor as well as methods for identifying, designing and using SARMs are provided.Type: ApplicationFiled: June 20, 2001Publication date: November 21, 2002Inventors: Mark E. Salvati, Marco M. Gottardis, Ricardo M. Attar, Stanley R. Krystek, John S. Sack